Risk of Clozapine-Associated Agranulocytosis and Mandatory White Blood Cell Monitoring

Abstract

Spanish

French

Objective:

To provide information for physicians and patients on which to base a decision as to whether to stop mandatory blood testing.

Data Sources:

Articles on drug-induced blood dyscrasias were identified by searches of MEDLINE (1966—September 2005) and review of their bibliographies. Novartis was asked to provide additional data on clozapine, leukopenia, agranulocytosis, and suicidality.

Study Selection and Data Extraction:

Data on the chance of clozapine-induced leukopenia and agranulocytosis were combined with data about possible fatality and compared with the risks associated with other medications and with life in general.

Data Synthesis:

The chance of clozapine-induced leukopenia or agranulocytosis decreases exponentially over time. In the US, the chance in the second 6 months of treatment is 0.70/1000 patient-years and, after the first year, 0.39/1000 patient-years. The case fatality rate of clozapine-induced agranulocytosis is estimated as 4.2–16%, depending on whether a granulocyte colony-stimulating factor is used. Nevertheless, treatment with clozapine reduces overall mortality, probably because it reduces suicidality.

Conclusions:

After at least 6 months' treatment with clozapine, the mortality involved in stopping white blood cell monitoring is about the same as the mortality associated with other medications, such as mianserin or phenylbutazone, and with life in general (traffic or occupational accident). If the patient has been well informed and wishes to stop the monitoring, it is a medically justifiable option to do so and is preferable to stopping treatment with clozapine since this drug reduces overall mortality.

Keywords

agranulocytosis clozapine

Get full access to this article

View all access options for this article.

References

EMEA. Committee for Proprietary Medicinal Products (CMPC) summary information on referral opinion following arbitration pursuant to Article 30 of Council Directive 2001/83/EC for Leponex and associated names. EMEA, London, 12-11–2002. www.emea.eu.int/pdfs/human/referral/603402en.pdf (accessed 2005 May 5).

Prescribing information. Clozaril (clozapine). November 2004. www.fda.gov/cder/foi/label/2005/019758s0541b1.pdf (accessed 2005 Sept 4).

FDA advisors back reduced monitoring for patients on clozapine. Reuters Health Information, June 16, 2003.

Walker

, Lanza

, Arellano

, Rothman

. Mortality in current and former users of clozapine. Epidemiology 1997;8:671–7.

Meltzer

, Anand

, Alphs

Reducing suicide risk in schizophrenia. Focus on the role of clozapine. CNS Drugs 2000;14:355–65.

Alvir

, Lieberman

, Safferman

, Schwimmer

, Schaaf

. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329:162–7.

Munro

, O'sullivan

, Andrews

, Arana

, Mortimer

, Kerwin

Active monitoring of 12760 clozapine recipients in the UK and Ireland. Br J Psychiatry 1999;175:576–80.

Kumar

Clozaril monitoring systems, registry data and analyses (United States, United Kingdom, & Australia), www.fda.gov/ohrms/dockets/ac/03/slides/3959S1_02_C-Novartis-Kumar.ppt (accessed 2005 Jul 1).

Patel

, Dorson

, Bettinger

. Sudden late onset of clozapine-induced agranulocytosis. Ann Pharmacother 2002;36:1012–5. DOI 10.1345/aph.1A417

10.

Kaufman

, Kelly

, Shapiro

Nonnarcotic analgesics and nonsteroidal anti-inflammatory drugs. In: Kaufman

, Kelly

, Shapiro

, eds. The drug etiology of agranulocytosis and aplastic anemia. Oxford: Oxford University Press, 1991: 170–203.

11.

Kaufman

, Kelly

, Shapiro

Cardiovascular drugs and diuretics. In: Kaufman

, Kelly

, Shapiro

, eds. The drug etiology of agranulocytosis and aplastic anemia. Oxford: Oxford University Press, 1991: 226–43.

12.

Heimpel

The diseases. In: Kaufman

, Kelly

, Shapiro

, eds. The drug etiology of agranulocytosis and aplastic anemia. New York: Oxford University Press, 1991: 27–69.

13.

Hummer

, Kurz

, Barnas

, Fleischhackker

. Transient neutropenia induced by clozapine. Psychopharmacol Bull 1992;28:287–90.

14.

Simpson

, Edmond

, Scarnac

. Neuroleptics and antipsychotics. In: Dukes

MNG

, ed. Meyler's side effects of drugs. 13th ed. Amsterdam: Elsevier Science BV, 1996: 117–35.

15.

Lamarque

[Hematologic effects of clozapine: a review of international experience] French. Encephale 1996;22(spec no 6):35–6.

16.

Grohmann

, Schmidt

, Spiess-Kiefer

, Rüther

Agranulocytosis and signficant leucopenia with neuroleptic drugs: results from the AMÜP program. Psychopharmacology 1989;99:109–12.

17.

Pisciotta

. Agranulocytosis induced by certain phenothiazine derivates. JAMA 1969;208:1862–8.

18.

Coulter

, Edwards

. Mianserin and agranulocytosis in New Zealand. Lancet 1990;336:785–7.

19.

Ibanez

, Ballarin

, Vidal

, Laporte

. Agranulocytosis associated with calcium dobesilate: clinical course and risk estimation with the case-control and the case population approaches. Eur J Clin Pharmacol 2000;56:763–7.

20.

Laporte

, Vidal

, Ballarin

, Ibanez

Possible association between ocular chloramphenicol and aplastic anaemia—the absolute risk is very low. Br J Pharmacol 1998;46:181–4.

21.

Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. JAMA 1986;256:1749–57.

22.

Risk of agranulocytosis and aplastic anaemia in relation to antithyroid drugs. International Agranulocytosis and Aplastic Anaemia Study. BMJ 1988;297:262–5.

23.

Kaufman

, Kelly

, Anderson

, Harmson

, Shapiro

Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997;38:1265–9.

24.

Kaufman

, Kelly

, Jurgelon

. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol 1996;60(suppl):23–30.

25.

Krupp

, Barnes

Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology 1989;99(suppl):118–21.

26.

Gullion

, Yeh

. Treatment of clozapine-induced agranulocytosis with recombinant granulocyte colony-stimulating factor. J Clin Psychiatry 1994;55:401–5.

27.

Gerson

. G-CSF and the management of clozapine induced agranulocytosis. J Clin Psychiatry 1994;55(suppl B):139–42.

28.

Julia

, Olona

, Bueno

Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Haematol 1991;79:366–71.

29.

Ban

, Ambrusics

, Pinter

[Occurrence and clinical course of drug-induced agranulocytosis] German. Folia Haematol Int Mag Klin Morphol Blutforsch 1985;112:90–102.

30.

Beauchesne

, Shalansky

. Nonchemotherapy drag-induced agranulocytosis: a review of 118 patients treated with colony-stimulating factors. Pharmacotherapy 1999;19:299–305.

31.

Coulter

, Edwards

. Mianserin and agranulocytosis in New Zealand. Lancet 1990;336:785–7.

32.

Glassman

, Bigger

. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774–82.

33.

Inman

. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. Br Med J 1977;1:1500–5.

34.

Statistics Netherlands. Unnatural death by causes, http://statline.cbs.nl/StatWeb/Table.asp?LA=nl&DM=SLNL&PA=37683&Dl=0-3,20-21,42-43,68,90-91,104-105,127-128&D2=0&D3=0&D4=a&STB=G1,G2,G3&HDR=T (accessed 2005 Jul 1).

35.

Meltzer

, Okayli

Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183–90.

36.

Reid

, Mason

, Hogan

Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr Serv 1998;49:1029–33.

37.

Meltzer

, Fatemi

Suicide in schizophrenia: the effect of clozapine. Clin Neuropharmacol 1995;18(suppl 13):18–24.

38.

Meltzer

, Alphs

, Green

. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82–91. Erratum 2003;60:735.

39.

Raymont

Suicide in schizophrenia: how can research influence training and clinical practice?

Psychiatr Bull 2001;25:46–50.

40.

Meltzer

. Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. Curr Psychiatry Rep 2002;4:279–83.

41.

Siris

. Suicide and schizophrenia. J Psychopharmacol 2001;15:127–35.

42.

Meltzer

. Suicide in schizophrenia: risk factors and clozapine treatment. J Clin Psychiatry 1998;59(suppl 3):200–8.

43.

WHO resource book on mental health, human rights and legislation. World Health Organization, 2005. www.who.int/mental_health/policy/resource_book_MHLeg.pdf (accessed 2005 Sept 9).

44.

Appelbaum

, Glisso

The MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR). Sarasota, FL: Professional Resource Press, 2001.

45.

Kovnick

, Appelbaum

, Hoge

, Leadbetter

. Competence to consent to research among long-stay inpatients with chronic schizophrenia. Psychiatr Serv 2003;54:1247–52.

46.

Dunn

, Jeste

. Problem areas in the understanding of informed consent for research: study of middle-aged and older patients with psychotic disorders. Psychopharmacology (Beri) 2003;171:81–5.

47.

Roberts

, Warner

, Brody

, Roberts

, Lauriello

, Lyketsos

Patient and psychiatrist ratings of hypothetical schizophrenia research protocols: assessment of harm potential and factors influencing participation decisions. Am J Psychiatry 2002;159:573–84.

48.

Stiles

, Poythress

, Hall

, Falkenbach

, Williams

Improving understanding of research consent disclosures among persons with mental illness. Psychiatr Serv 2001;52:780–5.

49.

Wirshing

, Wirshing

, Marder

, Liberman

, Mintz

Informed consent: assessment of comprehension. Am J Psychiatry 1998;155:1508–11.

50.

Eyler

, Mirzakhanian

, Jeste

. A preliminary study of interactive questioning methods to assess and improve understanding of informed consent among patients with schizophrenia. Schizophren Res 2005;75:193–8.

51.

Rapley

Quality of life research. A critical introduction. London: Sage Publications, 2003.

52.

Wang

, Ganz

, Benner

. Should clozapine continue to be restricted to third-line status for schizophrenia? A decision-analytic model. J Mental Health Policy Econ 2004;7:77–85.